|
March 2026
|
Laboratory Business Insights
Billing, Operational, and Staffing News for Laboratories
Presented by ADSRCM and ADS, Leading Providers of Outsourced Billing Service/Staffing or In-Laboratory Revenue Cycle Management Systems
.png?width=1200&height=1500&name=National%20Sales%20Manager%2c%20Laboratory%20(2).png)
A Message from Jim:
As we close the first quarter and look toward the remainder of 2026, the laboratory billing landscape has been reshaped by the Consolidated Appropriations Act and a series of operational shifts that extend far beyond rate adjustments.
For laboratory directors, CFOs, and operations leaders, this is not simply regulatory news — it is a strategic inflection point.
Between PAMA relief, updated reporting requirements, CLIA digital transitions, CPT and PLA expansion, prior authorization compression, and continued scrutiny of molecular reimbursement, the financial performance of your lab this year will depend heavily on execution discipline.
The defining theme of 2026 is precision.
Not volume.
Not optimism.
Not assumption.
Precision in documentation.
Precision in reporting.
Precision in reimbursement modeling.
Below, we break down what matters most — and where laboratory leaders should be focusing attention now.
— Jim O’Neill.
PAMA Relief: A Pause With Financial Consequence
The scheduled 15% reduction across approximately 800 CLFS tests has been delayed through December 31, 2026.
However, the reporting window between May 1 – July 31, 2026 will determine Medicare reimbursement rates for 2027–2029.
Labs must submit commercial payment data collected from January 1 – June 30, 2025.
This is not a clerical requirement.
It is a multi-year revenue modeling event.
A modest shift in median private payor rates can materially impact three years of Medicare reimbursement. For mid- to high-volume laboratories, that impact can reach six or seven figures.
The takeaway:
PAMA preparation is a balance sheet decision, not a billing task.
Evaluate Your PAMA Exposure
If your lab has not modeled the financial impact of 2027–2029 reimbursement shifts, our Lab Revenue Scorecard can help identify risk areas before submission.
Molecular Billing: PGx & CGx Under Continued Scrutiny
Pharmacogenomics (PGx) and broader genetic panels remain among the most sensitive reimbursement categories in 2026.
Coverage exists — particularly under Medicare — but it is tightly controlled.
Most reimbursement flows through the MolDX program administered by MACs such as Palmetto, CGS, Noridian, and WPS. Coverage typically requires:
• A registered DEX Z-code
• Drug-specific linkage (for PGx)
• Clear physician documentation
• Demonstrated clinical utility
MAC variability remains high. Commercial payer coverage remains uneven and often restrictive.
The operational implication is clear:
Coverage eligibility does not guarantee cash flow.
Documentation alignment, Z-code accuracy, and drug-specific justification now determine whether approved policies translate into payment.
Labs without structured molecular workflow oversight are seeing higher denial concentration and audit exposure.
Authorization Compression: Faster Denials, Not Fewer
Standard prior authorization decisions now require resolution within seven days. Expedited requests within 72 hours.
While timelines have shortened, documentation scrutiny has intensified.
Ordering provider documentation gaps now surface more quickly. Incomplete authorization workflows are resulting in faster denial cycles.
For laboratory operations leaders, this elevates authorization visibility to a financial control point.
Disconnected ordering and billing workflows are amplifying denial volatility.
Integrated documentation discipline is reducing rework.
CLIA Digital Transition & Audit Readiness
As of March 1, 2026, CMS eliminated paper CLIA fee coupons and certificates. All payments now flow through electronic systems.
Digital traceability is no longer administrative preference — it is compliance expectation.
For laboratories managing molecular complexity and payer variability, electronic audit readiness and data integrity now carry both regulatory and financial implications.
CPT & PLA Expansion: Mapping Risk Is Rising
The 2026 CPT cycle introduced significant code volatility, including the expansion of Proprietary Laboratory Analyses (PLA) codes.
Code change volume increases mapping risk across:
• Charge master alignment
• LIS mapping
• Clearinghouse edits
• Payer-specific configurations
Labs with delayed reconciliation are seeing elevated rejection rates and preventable claim delays.
The financial effects are subtle but cumulative.
Operational precision protects margin.
What This Means for Lab Leadership
Across our laboratory reviews, common patterns include:
• Denial rates between 7–12%
• 30–40% of denials left un-appealed
• Molecular claims carrying elevated documentation risk
• Manual PAMA reporting processes lacking audit safeguards
In 2026, billing is not administrative overhead.
It is strategic infrastructure.
Revenue stability now depends on:
• Structured documentation alignment
• Molecular workflow governance
• Accurate reimbursement modeling
• Payer performance visibility
• Proactive denial prevention
Lab Revenue Risk Snapshot
If your laboratory is:
• Preparing for the May PAMA reporting window
• Evaluating PGx or CGx reimbursement stability
• Experiencing elevated molecular denial rates
• Reviewing charge master and CPT mapping exposure
• Assessing multi-year reimbursement impact
You may benefit from a focused Lab Revenue Risk Snapshot.
The Opportunity
Even modest improvements can create measurable lift:
• 2–3% increase in clean claim rate
• 10-day reduction in A/R
• 5% increase in denial recovery
Without increasing test volume.
In today’s reimbursement climate, optimization is growth.
Let’s Continue the Conversation
If 2026 is prompting internal review of your lab’s revenue performance or molecular billing exposure, we’re available for a confidential discussion.
2026 is not simply a compliance year.
It is a defining financial year for laboratories.
.
Thanks for choosing ADS. Let’s keep building what works.
The ADSRCM Client Success Team - Laboratory Division
www.adsc.com/laboratory-billing-software
We hope you enjoyed the read.
Contact us about outsourced billing/staffing services (ADSRCM), or about MedicsPremier as an in-laboratory platform from ADS. We’ll help drive revenue and productivity in ways that work best for you. 800-899-4237, Ext. 2264 or info@adsc.com.
<<< >>>
Next Up:
April, with new articles and items of interest for laboratories!
We strive to provide our newsletters with news of the current month, not the previous month.
We greatly appreciate feedback or comments on our newsletters/content. Please opine by emailing christina.r@adsc.com or by calling 800-899-4237, Ext. 2264. We’d love to hear from you!
Disclaimer: Articles and content about governmental information, such as CMS, Medicare, and Medicaid, are presented according to our best understanding. Please visit www.cms.gov if clarifications are needed. We are not responsible for typographical errors or changes that may have occurred after this newsletter was produced. We don’t endorse any companies or organizations mentioned in our newsletters; you are encouraged to do research and due diligence on any that might interest you.
Keep up with the latest laboratory billing trends, insights, and industry news
Medical Billing / RCM | Laboratory
Billing Laboratory Tests Without LCDs: How Labs Can Stay Profitable Despite Coverage Gaps
By Jim O'Neill
on February 18th, 2026
Medical Billing / RCM | Laboratory
DOJ Enforcement of Clinical Laboratories: What Lab CFOs and Compliance Managers Need to Know Now
For clinical laboratories, compliance risk is no longer confined to the legal department. It is now ...
By Jim O'Neill
on February 11th, 2026
Medical Billing / RCM | Laboratory
Major PAMA Updates for 2026: What Clinical Laboratories Need to Know Now
Laboratory reimbursement is back in the spotlight and the stakes are higher than ever before.
By Jim O'Neill
on February 5th, 2026